Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7126)	9/2/1998 3:33:00 PM
From: Dan O	Read Replies (3) \| Respond to of 17367

Since Patterson is too much of a lazy piece of crap to make his own calls, and would rather criticize someone else for not doing his work for him, I made the call to Ellen today. She stated that she categorically reassures us that the study is not related to any takeover hostile or otherwise. They are simply trying to understand whether there will be big tax loss selling (which can be guestimated by knowing the acquisition date and price). The purpose of this is that it may influence year end stock price which could influence Xoma financing options. The reason the company did a poll as opposed to checking their own records is that many stockholders are not specifically registered with the company, but are instead beneficial holders (I think thats what she called it) where the company only knowns the name of the agency purchasing on their behalf. That is the story she relayed to me - believe it or not. Patterson, you can rest easy. You won't need to miss any Oprah episodes to make the call yourself you lazy piece of crap.

To: Bluegreen who wrote (7126)	9/2/1998 3:56:00 PM
From: aknahow	Read Replies (3) \| Respond to of 17367

Yes XOMA could stop the trial on its' own without a recommendation to do so by the DSMB. This would be considered a gamble because it is blinded to the data. It would be taking a chance, that what you and I believe is correct, is worth disrupting the on going trials and acting in the face of a DSMB recommendation to continue. The benefits which we both agree on probably do not outweigh simply completing the trial as agreed to if the DSMB recommends proceeding and states there are no safety concerns. As you post, stopping the trial early when the DSMB recommends continuation would be a, "drastic measure." I do not think it would be good management to do it right, get this far and then resort to a drastic measure, or bet that they can save some money, get to market sooner and see the stock rally, by a unilateral decision to halt early. Now why does MacCamant say they will? Perhaps he has contacted some of the trial sites and is getting information that enables him to feel the DSMB will recommend an early halt. I have no such information, but I do believe that those doing the treating probably recognize something which makes them think they know who was treated.